Stem cells have grabbed headlines for decades. Now, at last, they are starting to deliver on their therapeutic promise, with multiple stem cell therapies in clinical trials for Parkinson’s disease. This episode of our award-winning “Parkinson’s Science POV” series brings us up to date on these trials, including how scientists are using stem cells to replace dopamine, the chemical that’s lost in Parkinson's disease.
If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet. If you enjoyed what you heard, share it with a friend or leave a review on iTunes. It helps listeners like you find and support our mission.
Join Maggie Kuhl, vice president of research engagement at The Michael J. Fox Foundation (MJFF), as she leads a discussion about the latest research on stem cells for Parkinson’s with our two expert panelists:
Brian Fiske, PhD, MJFF chief science officer.
Harini Sarva, MD, director of the Parkinson’s Disease and Movement Disorders Center, associate professor of clinical neurology and lead clinical trialist for movement disorders at Weill Cornell Medicine. She is also a principal investigator of BlueRock’s clinical trial on stem cell-based therapy bemdaneprocel (BRT-DA01) for Parkinson’s disease.
Join a study today to help speed progress toward better treatments and a cure for Parkinson’s disease. To search for studies in your area, visit Fox Trial Finder.
Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything.